Artivion Wins FDA PMA as CryoPort Hits EBITDA Breakeven: Medtech Inflection in Q2 2026

The Quick Take

• Artivion (AORT) reports 9% constant currency revenue growth in Q2 2026, FDA PMA approval achieved for its surgical aortic device, and Endospan acquisition integration underway
• CryoPort (CYRX) achieves positive adjusted EBITDA for the first time in company history, reaffirming full-year guidance as biostorage and cold-chain logistics for cell therapy scales
• Both companies mark the medtech EBITDA inflection theme — smaller devices and biologics logistics firms reaching cash-flow breakeven as cell therapy and aortic repair markets mature

Two medtech companies reported Q2 2026 results that collectively mark an important sector transition: specialty medical device and biological logistics firms moving from growth-at-all-costs to profitable scale. Artivion Inc (AORT) reported 9% constant currency revenue growth, with its stent graft and ONIX aortic repair platform ahead of expectations, and disclosed completion of the Endospan acquisition that extends its minimally invasive aortic repair portfolio into a new clinical segment.

The most significant milestone for Artivion was receiving FDA Pre-Market Approval (PMA) for its surgical aortic device — a regulatory achievement that clears the path for broader hospital adoption. PMA status typically unlocks accelerated hospital formulary inclusion, particularly in large health systems that require PMA-cleared implants before committing to long-term supply agreements. Management noted the Endospan integration is progressing ahead of schedule with limited disruption to existing product lines.

CryoPort Inc (CYRX) crossed a critical financial threshold in Q2, achieving positive adjusted EBITDA for the first time in its history — validating the unit economics of its cold-chain logistics and biostorage infrastructure for cell and gene therapy supply chains. The company reaffirmed its full-year revenue guidance, citing strong biostorage segment growth as a leading indicator of maturing commercial pipelines from its biopharma customers. Together, Artivion's PMA milestone and CryoPort's EBITDA breakeven signal that the medtech enablement layer — device implants and biological logistics — is entering a new phase of profitable, durable growth.

Synthesized from 2 sources.